260 related articles for article (PubMed ID: 11023670)
21. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone.
Grigorieva I; Thomas X; Epstein J
Exp Hematol; 1998 Jul; 26(7):597-603. PubMed ID: 9657134
[TBL] [Abstract][Full Text] [Related]
22. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6.
Westendorf JJ; Ahmann GJ; Greipp PR; Witzig TE; Lust JA; Jelinek DF
Leukemia; 1996 May; 10(5):866-76. PubMed ID: 8656685
[TBL] [Abstract][Full Text] [Related]
23. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
24. In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma.
Portier M; Rajzbaum G; Zhang XG; Attal M; Rusalen C; Wijdenes J; Mannoni P; Maraninchi D; Piechaczyk M; Bataille R
Eur J Immunol; 1991 Jul; 21(7):1759-62. PubMed ID: 2060582
[TBL] [Abstract][Full Text] [Related]
25. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells.
Wang YD; De Vos J; Jourdan M; Couderc G; Lu ZY; Rossi JF; Klein B
Oncogene; 2002 Apr; 21(16):2584-92. PubMed ID: 11971193
[TBL] [Abstract][Full Text] [Related]
26. [Production of interleukin-1 and interleukin-6 in a culture of mononuclear cells of peripheral blood and bone marrow in multiple myeloma].
Kliushnenkova EN; Lutskaia TD; Golenkov AK; Malaĭtsev VV
Biull Eksp Biol Med; 1993 May; 115(5):507-10. PubMed ID: 8043836
[TBL] [Abstract][Full Text] [Related]
27. Homing mechanisms in the biology of multiple myeloma.
Van Camp B; Van Riet I
Verh K Acad Geneeskd Belg; 1998; 60(3):163-94. PubMed ID: 9803879
[TBL] [Abstract][Full Text] [Related]
28. Requirement of soluble factors produced by bone marrow stromal cells on the growth of novel established human myeloma cell line.
Aikawa S; Hatta Y; Tanaka M; Kaneita Y; Yasukawa K; Sawada U; Horie T; Tsuboi I; Aizawa S
Int J Oncol; 2003 Mar; 22(3):631-7. PubMed ID: 12579318
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of interleukin-6 gene expression in the bone marrow of patients with multiple myeloma.
Iwasaki T; Hamano T; Ogata A; Kakishita E
Int J Hematol; 1999 Oct; 70(3):163-8. PubMed ID: 10561908
[TBL] [Abstract][Full Text] [Related]
30. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
31. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
32. Antimyeloma effects of a sesquiterpene lactone parthenolide.
Suvannasankha A; Crean CD; Shanmugam R; Farag SS; Abonour R; Boswell HS; Nakshatri H
Clin Cancer Res; 2008 Mar; 14(6):1814-22. PubMed ID: 18347184
[TBL] [Abstract][Full Text] [Related]
33. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.
Hideshima T; Chauhan D; Schlossman R; Richardson P; Anderson KC
Oncogene; 2001 Jul; 20(33):4519-27. PubMed ID: 11494147
[TBL] [Abstract][Full Text] [Related]
34. Interaction between a murine myeloma cell line and bone marrow stromal cells.
Bradley TR; Kriegler AB; Verschoor SM; Tzelepis SM; Cooper IA
Exp Hematol; 1996 Feb; 24(2):307-9. PubMed ID: 8641357
[TBL] [Abstract][Full Text] [Related]
35. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
Standal T; Hjorth-Hansen H; Rasmussen T; Dahl IM; Lenhoff S; Brenne AT; Seidel C; Baykov V; Waage A; Børset M; Sundan A; Hjertner O
Haematologica; 2004 Feb; 89(2):174-82. PubMed ID: 15003892
[TBL] [Abstract][Full Text] [Related]
36. A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment.
Sekimoto E; Ozaki S; Ohshima T; Shibata H; Hashimoto T; Abe M; Kimura N; Hattori K; Kawai S; Kinoshita Y; Yamada-Okabe H; Tsuchiya M; Matsumoto T
Cancer Res; 2007 Feb; 67(3):1184-92. PubMed ID: 17283154
[TBL] [Abstract][Full Text] [Related]
37. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
38. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect.
Corso A; Ferretti E; Lunghi M; Zappasodi P; Mangiacavalli S; De Amici M; Rusconi C; Varettoni M; Lazzarino M
Cancer; 2005 Jul; 104(1):118-25. PubMed ID: 15895374
[TBL] [Abstract][Full Text] [Related]
39. [The mechanisms of myeloma cell growth].
Shimizu S
Nihon Rinsho; 1995 Mar; 53(3):557-63. PubMed ID: 7699885
[TBL] [Abstract][Full Text] [Related]
40. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression.
Kline M; Donovan K; Wellik L; Lust C; Jin W; Moon-Tasson L; Xiong Y; Witzig TE; Kumar S; Rajkumar SV; Lust JA
Leuk Res; 2007 May; 31(5):591-8. PubMed ID: 16879867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
